Beam Therapeutics shares are trading lower after Jefferies downgraded the stock from Buy to Hold and lowered its price target from $75 to $30.
Portfolio Pulse from Benzinga Newsdesk
Beam Therapeutics' stock price has declined following a downgrade by Jefferies from Buy to Hold, accompanied by a significant reduction in the price target from $75 to $30.
December 08, 2023 | 5:49 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Beam Therapeutics' shares are expected to face downward pressure in the short term due to the downgrade by Jefferies from Buy to Hold and a substantial decrease in the price target.
Analyst downgrades typically lead to a negative perception among investors, potentially causing a sell-off. The significant reduction in the price target from $75 to $30 by a reputable firm like Jefferies suggests a substantial change in the expected performance of the company, which could lead to a decrease in investor confidence and a drop in the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100